Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Edgewise Therapeutics Inc. (EWTX)

NASDAQ: EWTX · Pharmaceutical Preparations · Boulder, CO

Our rating: Positive

Call changed from Neutral to Positive at $45.04, moderate conviction, November 6, 2026.

Breaks if: The Positive call breaks if any lead program produces a pivotal-trial failure or receives a complete-response letter within the next 12 months, or if two consecutive quarterly filings show cash burn accelerating beyond $50M per quarter with no accompanying financing close — implying runway contracting below eight quarters and forcing dilutive capital raises. On price terms, a sustained drawdown of 35% or more from $45.04 within the next 12 months would signal the market has repriced pipeline risk toward zero and would require a full reassessment of the thesis.

Key figures

Market value$4.4B
Revenue, last 12 monthsn/a
Net income, last 12 months$1.0B
Free cash flow, last 12 months−$202M
Price to earnings4.3×
Free cash flow yield−4.6%
Dividend yield0.0%
Operating marginn/a
Return on equity92.1%
Beta to the S&P 5001.29
Volatility, annualized78.1%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026n/an/a$9.65−$78M
June 30, 2026n/an/a$-0.53−$43M
March 31, 2026n/an/a$-0.46−$43M
December 31, 2025n/an/a$-0.48−$39M
September 30, 2025n/an/a$-0.39−$35M
June 30, 2025n/an/a$-0.34−$33M
March 31, 2025n/an/a$-0.43−$38M
December 31, 2024n/an/a$-0.42−$27M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

26 ledger entries and 18 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.